Grønning, Rebecca
Jeppsson, Anna
Hellström, Per
Laurell, Katarina
Farahmand, Dan
Zetterberg, Henrik
Blennow, Kaj
Wikkelsø, Carsten
Tullberg, Mats
Article History
Received: 19 April 2023
Accepted: 6 October 2023
First Online: 25 October 2023
Declarations
:
: This study was performed in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Review Board in Gothenburg (Dnr 328-14, T439-15). All patients or their next of kin gave written consent to inclusion in the study.
: All authors gave their consent for publication.
: HZ has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the Gothenburg University Ventures Incubator Program. The other authors declare no competing interests.